Amino terminal pro-B-type natriuretic peptide, secondary stroke prevention, and choice of antithrombotic therapy

Stroke

Volumn 44, Issue 3, 2013, Pages 714-719

  Longstreth Jr , W T ^a,b   Kronmal, Richard A ^b   Thompson, John L P ^c   Christenson, Robert H ^f   Levine, Steven R ^g   Gross, Rebecca ^c   Brey, Robin L ^c   Buchsbaum, Richard ^h   Elkind, Mitchell S V ^d,e   Tirschwell, David L ^a   Seliger, Stephen L ^f   Mohr, J P ^e   De Filippi, Christopher R ^f  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Division of Biostatistics and Epidemiology   (United States)

^d Mailman School of Public Health   (United States)

^e Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^g SUNY DOWNSTATE MEDICAL CENTER   (United States)

^h UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Aspirin; NT proBNP; Secondary stroke prevention; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SECONDARY PREVENTION;

AGED; ANTICOAGULANTS; ASPIRIN; BIOLOGICAL MARKERS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PLATELET AGGREGATION INHIBITORS; RECURRENCE; STROKE; TREATMENT OUTCOME; WARFARIN;

EID: 84876286491     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.112.675942     Document Type: Article

References (32)

1. Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart. 2006;92:843-849.
2. deFilippi CR, Christenson RH, Gottdiener JS, Kop WJ, Seliger SL. Dynamic cardiovascular risk assessment in elderly people. The role of repeated N-terminal pro-B-type natriuretic peptide testing. J Am Coll Cardiol. 2010;55:441-450.
3. Patton KK, Ellinor PT, Heckbert SR, Christenson RH, DeFilippi C, Gottdiener JS, et al. N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study. Circulation. 2009;120:1768-1774.
4. Di Angelantonio E, De Castro S, Toni D, Sacchetti ML, Biraschi F, Prencipe M, et al. Determinants of plasma levels of brain natriuretic peptide after acute ischemic stroke or TIA. J Neurol Sci. 2007;260:139-142.
5. Montaner J, Perea-Gainza M, Delgado P, Ribó M, Chacón P, Rosell A, et al. Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke. 2008;39:2280-2287.
6. Naya T, Yukiiri K, Hosomi N, Takahashi T, Ohkita H, Mukai M, et al. Brain natriuretic peptide as a surrogate marker for cardioembolic stroke with paroxysmal atrial fibrillation. Cerebrovasc Dis. 2008;26:434-440.
7. Yukiiri K, Hosomi N, Naya T, Takahashi T, Ohkita H, Mukai M, et al. Plasma brain natriuretic peptide as a surrogate marker for cardioembolic stroke. BMC Neurol. 2008;8:45.
8. Shibazaki K, Kimura K, Iguchi Y, Okada Y, Inoue T. Plasma brain natriuretic peptide can be a biological marker to distinguish cardioembolic stroke from other stroke types in acute ischemic stroke. Intern Med. 2009;48:259-264.
9. Rodríguez-Yáñez M, Sobrino T, Blanco M, de la Ossa NP, Brea D, Rodríguez-González R, et al. High serum levels of pro-brain natriuretic peptide (pro BNP) identify cardioembolic origin in undetermined stroke. Dis Markers. 2009;26:189-195.
10. Fonseca AC, Matias JS, Pinho e Melo T, Falcão F, Canhão P, Ferro JM. N-terminal probrain natriuretic peptide as a biomarker of cardioembolic stroke. Int J Stroke. 2011;6:398-403.
11. Shibazaki K, Kimura K, Fujii S, Sakai K, Iguchi Y. Brain natriuretic peptide levels as a predictor for new atrial fibrillation during hospitalization in patients with acute ischemic stroke. Am J Cardiol. 2012;109:1303-1307.
12. Rost NS, Biffi A, Cloonan L, Chorba J, Kelly P, Greer D, et al. Brain natriuretic peptide predicts functional outcome in ischemic stroke. Stroke. 2012;43:441-445.
13. Sharma JC, Ananda K, Ross I, Hill R, Vassallo M. N-terminal proBrain natriuretic peptide levels predict short-term poststroke survival. J Stroke. Cerebrovasc Dis. 2006;15:121-127.
14. Yip HK, Sun CK, Chang LT, Chen MC, Liou CW. Time course and prognostic value of plasma levels of N-terminal pro-brain natriuretic peptide in patients after ischemic stroke. Circ J. 2006;70:447-452.
15. Tomita H, Metoki N, Saitoh G, Ashitate T, Echizen T, Katoh C, et al. Elevated plasma brain natriuretic peptide levels independent of heart disease in acute ischemic stroke: correlation with stroke severity. Hypertens Res. 2008;31:1695-1702.
16. Whiteley W, Wardlaw J, Dennis M, Lowe G, Rumley A, Sattar N, et al. The use of blood biomarkers to predict poor outcome after acute transient ischemic attack or ischemic stroke. Stroke. 2012;43:86-91.
17. Campbell DJ, Woodward M, Chalmers JP, Colman SA, Jenkins AJ, Kemp BE, et al. Soluble vascular cell adhesion molecule 1 and N-terminal pro-B-type natriuretic peptide in predicting ischemic stroke in patients with cerebrovascular disease. Arch Neurol. 2006;63:60-65.
18. Mäkikallio AM, Mäkikallio TH, Korpelainen JT, Vuolteenaho O, Tapanainen JM, Ylitalo K, et al. Natriuretic peptides and mortality after stroke. Stroke. 2005;36:1016-1020.
19. Jensen JK, Mickley H, Bak S, Korsholm L, Kristensen SR. Serial measurements of N-terminal pro-brain natriuretic peptide after acute ischemic stroke. Cerebrovasc Dis. 2006;22:439-444.
20. Shibazaki K, Kimura K, Okada Y, Iguchi Y, Uemura J, Terasawa Y, et al. Plasma brain natriuretic peptide as an independent predictor of in-hospital mortality after acute ischemic stroke. Intern Med. 2009;48:1601-1606.
21. Jensen JK, Atar D, Kristensen SR, Mickley H, Januzzi JL Jr. Usefulness of natriuretic peptide testing for long-term risk assessment following acute ischemic stroke. Am J Cardiol. 2009;104:287-291.
22. Shibazaki K, Kimura K, Iguchi Y, Aoki J, Sakai K, Kobayashi K. Plasma brain natriuretic peptide predicts death during hospitalization in acute ischaemic stroke and transient ischaemic attack patients with atrial fibrillation. Eur J Neurol. 2011;18:165-169.
23. Levine SR, Brey RL, Tilley BC, Thompson JL, Sacco RL, Sciacca RR, et al.; APASS Investigators. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004;291:576-584.
24. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, et al.; Warfarin-Aspirin Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345:1444-1451.
25. Ordonez-Llanos J, Collinson PO, Christenson RH. Amino-terminal pro-B-type natriuretic peptide: analytic considerations. Am J Cardiol. 2008;101(3A):9-15.
26. Homma S, Thompson JL, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR, et al.; WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med. 2012;366:1859-1869.
27. Januzzi JL Jr. The role of natriuretic peptide testing in guiding chronic heart failure management: review of available data and recommendations for use. Arch Cardiovasc Dis. 2012;105:40-50.
28. Seet RC, Friedman PA, Rabinstein AA. Prolonged rhythm monitoring for the detection of occult paroxysmal atrial fibrillation in ischemic stroke of unknown cause. Circulation. 2011;124:477-486.
29. Nakagawa K, Yamaguchi T, Seida M, Yamada S, Imae S, Tanaka Y, et al. Plasma concentrations of brain natriuretic peptide in patients with acute ischemic stroke. Cerebrovasc Dis. 2005;19:157-164.
30. Giannakoulas G, Hatzitolios A, Karvounis H, Koliakos G, Charitandi A, Dimitroulas T, et al. N-terminal pro-brain natriuretic peptide levels are elevated in patients with acute ischemic stroke. Angiology. 2005;56:723-730.
31. Shibazaki K, Kimura K, Okada Y, Iguchi Y, Terasawa Y, Aoki J. Heart failure may be associated with the onset of ischemic stroke with atrial fibrillation: a brain natriuretic peptide study. J Neurol Sci. 2009;281:55-57.
32. Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation. 2012;125:1605-1616.